Tag: american

Evelyn Mullen named American Nuclear Society Fellow | US Department of Energy Science News

13-Oct-2020

DOE/Los Alamos National Laboratory

Evelyn Mullen, chief operating officer for Global Security at Los Alamos National Laboratory, was named a fellow of the American Nuclear Society.


LOS ALAMOS, N.M., Oct. 13, 2020–Evelyn Mullen, chief operating officer for Global Security at Los Alamos National Laboratory, was named a fellow of the American Nuclear Society for her leadership in nuclear national security and ensuring the nation’s experimental capability in nuclear criticality.

“For more than 25 years, Evelyn Mullen has displayed outstanding leadership in nuclear and radiological threat response,” said Nancy Jo Nicholas, associate Laboratory director for Global Security at Los Alamos. “She has provided intellectual leadership for planning and executing science and technology for nuclear nonproliferation, detection, render safe, and attribution; foreign nuclear weapon analysis; and nuclear detonation response and recovery issues. Being named an ANS Fellow is a well-deserved honor for someone who has contributed so much to the field.”

Mullen was instrumental in developing plans for new diagnostic capabilities for subcritical plutonium-integrated experiments at the Nevada National Security Site that will become operational in 2025. Furthermore, she currently leads a major effort for recovery from a radiation source accident in Seattle, Wash.

Mullen joined Los Alamos National Laboratory in 1992. She holds bachelor and master of science degrees in nuclear engineering and is a registered professional engineer in the State of New Mexico. She currently serves on the Army Science Board. Mullen has volunteered with the Los Alamos National Laboratory Foundation on the scholarship and grants committees for many years and is a founding member of the Legacy Society. Mullen is also a founding member of the Los Alamos Community Foundation and has been recognized by the Los Alamos Engineering Council with their community service award.

Established in 1954, the American Nuclear Society is an international professional organization of engineers and scientists devoted to the peaceful applications of nuclear science and technology. Its more than 9,500 members represent government, academia, research laboratories, medical facilities, and private industry. ANS’s mission is to advance, foster, and spur the development and application of nuclear science, engineering, and technology to benefit society.


###

About Los Alamos National Laboratory

Los Alamos National Laboratory, a multidisciplinary research institution engaged in strategic science on behalf of national security, is managed by Triad, a public service oriented, national security science organization equally owned by its three founding members: Battelle Memorial Institute (Battelle), the Texas A&M University System (TAMUS), and the Regents of the University of California (UC) for the Department of Energy’s National Nuclear Security Administration.

Los Alamos enhances national security by ensuring the safety and reliability of the U.S. nuclear stockpile, developing technologies to reduce threats from weapons of mass destruction, and solving problems related to energy, environment, infrastructure, health, and global security concerns.

 

Source Article

Continue reading

American Cancer Society and Chevrolet Celebrate 10-Year Partnership in Fight Against Breast Cancer

While Making Strides events have gone virtual this year, Chevrolet will continue support the events at the national, regional and local level all month. Employees across the country are participating in local Making Strides Against Breast Cancer events by “walking where they are” and making donations.

On October 1, Chevrolet launched its monthlong #IDriveFor social media campaign, which encourages people to share whom they drive for using the hashtag. Chevrolet will contribute $5 for every social post (up to $220,000) on Twitter or Instagram using #IDriveFor.

Chevrolet is also showing its support for Breast Cancer Awareness Month and Making Strides by turning the towers of the Renaissance Center global headquarters in Detroit pink during October, displaying a pink fleet of vehicles and painting the sidewalks in front of the Renaissance Center pink.

“We are more grateful than ever for Chevrolet’s partnership, 10 years strong,” said Gary Reedy, chief executive officer of the American Cancer Society. “Cancer hasn’t stopped for COVID-19. Chevy’s continued commitment to Making Strides, ensures we can fund the future and continue the progress we have made in the fight against breast cancer through groundbreaking research, providing access to care and providing screenings for those who need it most.”

“Many things look different today than they did a year ago, but the commitment by ACS to continue the fight against breast cancer remains unwavering,” said Steve Majoros, U.S. vice president, Chevrolet Marketing. “Chevy is proud to continue our commitment to Making Strides with the rollout of the #IDriveFor campaign. We are excited to leverage technology to create a virtual community fueled by the shared mission of raising awareness of and financial support for breast cancer research.”

To learn more about Making Strides, visit makingstrideswalk.org.

About Chevrolet
Founded in 1911 in Detroit, Chevrolet is one of the world’s largest car brands, doing business in more than 100 countries and selling more than 4 million cars and trucks a year. Chevrolet provides customers with fuel-efficient vehicles that feature engaging performance, design that makes the heart beat, passive and active safety features and easy-to-use technology, all at a value. More information on Chevrolet models can be found at www.chevrolet.com.

About the American Cancer Society

The American Cancer Society is a global grassroots force of 1.5 million volunteers dedicated to saving lives, celebrating lives, and leading the fight for a world without cancer. From breakthrough research, to free lodging near treatment, a 24/7/365 live helpline, free rides to treatment, and convening powerful activists to create awareness and impact, the Society is the only organization attacking cancer from every angle. For more information go to www.cancer.org.

Media Contact: Amanda Bosherz, [email protected]

SOURCE American Cancer Society Michigan

Source Article

Continue reading

Bayer to Present Results From Phase III FIDELIO-DKD Study with Finerenone in Patients with Chronic Kidney Disease and Type 2 Diabetes during Late-Breaker Session at the American Society of Nephrology’s Kidney Week 2020

WHIPPANY, N.J.–(BUSINESS WIRE)–Bayer will present detailed results from the Phase III FIDELIO-DKD study assessing the use of the investigational drug finerenone on kidney and cardiovascular outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) during scientific sessions of the upcoming American Society of Nephrology’s (ASN) Kidney Week, October 22-25, 2020. Additional data evaluating use of finerenone will also be presented.

The FIDELIO-DKD study, which evaluated the efficacy and safety of finerenone versus placebo when added to standard of care in patients with CKD and T2D, is the first large contemporary positive outcomes study in patients with CKD and T2D with a primary composite endpoint exclusively consisting of kidney-specific outcomes. Bayer announced earlier this year that FIDELIO-DKD met its composite primary renal endpoint and its composite key secondary cardiovascular endpoint.

Full data from the FIDELIO-DKD study will be presented as part of the live-streamed, late-breaker oral abstract session High-Impact Clinical Trials:

  • “Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes” – October 23, 2020, 10:30 –10:45 am (EDT) (Abstract FR-OR51)

Additional scientific presentations include:

About the Finerenone Phase III Clinical Program

Finerenone (BAY 94-8862) is an investigational, non-steroidal, selective mineralocorticoid receptor antagonist.1 The Phase III clinical program with finerenone in CKD and T2D is the largest Phase III clinical trial program to date in CKD and T2D having 13,000 randomized patients across a broad range of disease severity including those with early kidney damage and more advanced stages of kidney disease. The clinical program comprises two studies (FIDELIO-DKD and FIGARO-DKD), evaluating the effect of finerenone versus placebo in addition to the standard of care in both renal and cardiovascular outcomes.

FIDELIO-DKD (FInerenone in reducing kiDnEy faiLure and dIsease prOgression in Diabetic Kidney Disease) is a randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study that investigated the efficacy and safety of finerenone in comparison to placebo in addition to standard of care on the reduction of kidney failure and kidney disease progression in approximately 5,700 patients with CKD and T2D from more than 1,000 sites across 48 countries worldwide.

FIGARO-DKD (FInerenone in reducinG cArdiovascular moRtality and mOrbidity in Diabetic Kidney Disease) is still ongoing and is investigating the efficacy and safety of finerenone versus placebo in addition to standard of care on the reduction of cardiovascular morbidity and mortality in approximately 7,400 patients with CKD and T2D across 47 countries including sites in Europe, Japan, China and the U.S.

Bayer also recently announced the initiation of the FINEARTS-HF study, a multicenter, randomized, double-blind, placebo-controlled Phase III study which will investigate finerenone compared to placebo in more than 5,500 symptomatic heart failure patients (New York Heart Association class II-IV) with a left ventricular ejection fraction of ≥40%. The primary objective of the study is to demonstrate superiority of finerenone over placebo in

Continue reading

Castle Biosciences Presents Data at the 2020 American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting


Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that its data were featured in two oral presentations during the 2020 American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting, Oct. 9-11, 2020.


DecisionDx®-Melanoma: Skin Cancer and Reconstruction Session; Friday, October 9, 2020


“Cutaneous Melanoma Prognostic Model Combining 31-gene Expression Profile and Sentinel Lymph Node Biopsy” was presented by Aaron Farberg, M.D., Baylor University Medical Center, Dallas, Texas.


DecisionDx-Melanoma is a gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of cutaneous melanoma metastasis or recurrence, as well as sentinel lymph node positivity, independent of traditional staging factors.


“As most sentinel lymph node biopsies are negative, there is a need to identify which melanoma patients can forgo sentinel lymph node biopsy (SNLB),” said Dr. Farberg. “Based on the cohort described in a recent meta-analysis by Greenhaw and colleagues, we modeled the use of Castle’s DecisionDx-Melanoma test to determine whether it might alter the predictive value of SLNB alone in high-risk patients, and whether the test might identify patients who would not benefit from SLNB. In fact, we found that use of the test stratifies risk in the cohort studied, which can help focus the resources needed for SLNB on patients with genuinely higher risk, thereby reducing surgical risks for patients who can avoid SLNB.”


Study methods and findings:


  • The study objective was to model the use of DecisionDx-Melanoma to triage cutaneous melanoma patients for SLNB, to evaluate the outcomes of low-risk patients who can forgo SLNB and to evaluate the combined accuracy of DecisionDx-Melanoma and SLNB in high-risk patients.

  • The model was based on use of DecisionDx-Melanoma to triage the patients from the recently published systematic review and meta-analysis (Greenhaw et al. JAAD, Sept., 2020), assuming that:

    • Patients with a Class 1A result who were 55 years of age or older with T1-T2 melanoma would not undergo SLNB;

    • The negative predictive value of DecisionDx-Melanoma for recurrence-free survival, distant metastasis free survival and ultimately melanoma specific survival would be high for patients who would not have undergone SLNB due to DecisionDx-Melanoma triage; and

    • The remaining patients would undergo SLNB.

  • Result showed that:

    • 69% of all patients could forgo an SLNB due to a DecisionDx-Melanoma Class 1A test result, and the negative predictive value for 5-year melanoma specific survival was 98%.

    • For the remaining 31% of patients who would undergo an SLNB:

      • Sensitivity for melanoma specific death was 87% for DecisionDx-Melanoma compared with 73% for SLNB. Combining DecisionDx-Melanoma with SLNB improved sensitivity to 96%.

      • Negative predictive value for melanoma specific death was 95% for DecisionDx-Melanoma, compared with 94% for SLNB. Combining DecisionDx-Melanoma with SLNB improved negative predictive value to 98%.

  • The study concluded that use of DecisionDx-Melanoma to triage patients with
Continue reading

KAHR Announces Oral Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting

JERUSALEM, Oct. 12, 2020 /PRNewswire/ — KAHR, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, today announced that an abstract reporting preclinical data for DSP107, a second generation CD47x41BB targeting compound for the treatment of solid tumors and hematological malignancies, has been accepted for an oral presentation at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, taking place virtually from December 5-8, 2020.

“The ASH Annual Meeting will be an important opportunity to present mechanistic studies and extensive in vitro and in vivo results from our novel CD47x41BB clinical stage drug candidate,” said Yaron Pereg, Ph.D., Chief Executive Officer of KAHR. “We look forward to advancing the clinical development of this novel therapy.”

The following abstract will be posted on the ASH website on November 5, 2020, at 9:00 a.m. ET:

Title: DSP107, a Novel Bi-Functional Fusion Protein That Combines Inhibition of CD47 with Targeted Activation of 4-1BB to Trigger Innate and Adaptive Anticancer Immune Responses

Publication Number: 173
Session Name: 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Session Date: Saturday, December 5, 2020
Session Time: 12:00 PM – 1:30 PM
Presentation Time: 12:30 PM

Session Name: 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Novel Approaches to Overcome Resistance

About DSP107

DSP107 targets CD47-overexpressing tumors, simultaneously blocking macrophage inhibitory signals and delivering an immune costimulatory signal to tumor antigen-specific, activated T-cells.  CD47 is overexpressed on many cancer cells and binds SIRPα on immune phagocytic cells to produce a “don’t eat me” signal.  DSP107 binds CD47 on cancer cells, blocking interaction with SIRPα and thus, blocking the “don’t eat me signal”. Simultaneously, DSP107 binds 41BB on T-cells, stimulating their activation. These activities lead to targeted immune activation through both macrophage and T-cell mediated tumor destruction. 

About DPS107 Phase I/II

A Phase I/II clinical trial to evaluate the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of DSP107 as a monotherapy and in combination with Roche’s PD-L1-blocking checkpoint inhibitor (CPI) atezolizumab (Tecentriq®) in patients with advanced solid tumors is currently being activated. The preliminary efficacy of both DSP107 monotherapy and combination therapy with atezolizumab will also be evaluated in patients with advanced non-small-cell lung carcinoma (NSCLC) who progressed after treatment with PD-1/PD-L1 inhibitors. The study will be conducted at multiple centers in the United States under a clinical collaboration with Roche.

About KAHR

KAHR develops the next generation of immuno-oncology drug candidates for the treatment of multiple types of cancer. The Company’s lead product, DSP107, is a second generation CD47x41BB targeting compound that simultaneously targets cancer cells, weakens their innate defenses and activates an effective, local response of both innate and adaptive immunity. KAHR’s technology platform is based on multi-functional immuno-recruitment proteins (MIRP) that utilize overexpression of checkpoint antigens on cancer cells in order to selectively target and bind to the tumor. MIRPs binding cancer cells to immune cells to produce a targeted synergistic effect by combining immune checkpoint inhibition with localized immune cell activation, unmasking cancer cell camouflage to enable innate immune response, while recruiting

Continue reading

American Horticultural Society faces an uncertain future

On paper at least, the American Horticultural Society, founded in 1922, should be poised to move into its second century as a major player in the green world, an organization with a compelling mission and a rosy future.

The pandemic has reinforced the importance of gardens and gardening, reflected in surging vegetable seed sales and the desire of people to visit public gardens and other green spaces to find succor in anxious times.

        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

 

COVID-19 aside, public gardens offer enormous potential to connect an ever urbanizing population to a planet in environmental crisis and to bring together diverse groups at a time of social, political and economic unrest.

But the AHS, located at its pastoral 25-acre property on the Potomac, River Farm, is facing its own moment of reckoning.

Citing the pandemic as a contributor, the society recently announced on its website that it was considering leaving River Farm, merging in some unspecified fashion with the American Public Gardens Association, and putting the prime piece of real estate on the market. This is a situation much in flux — the society’s board is said to be reevaluating its options after a backlash to the plan — but it is clear that the nonprofit is at some sort of existential crossroad.

Like other such organizations — in the United States, examples include the venerable Pennsylvania Horticultural Society and the Massachusetts Horticultural Society — the AHS was formed to guide and promote the plant and garden passions of its members. It puts out a glossy magazine, the American Gardener; has published garden books and encyclopedias; holds workshops and symposiums; and has organized travel study trips to gardens around the world. It was a pioneer in the children’s and youth garden movements. The property was once part of one of George Washington’s satellite farms and sits a few miles north of Washington’s Mount Vernon estate on the Virginia side of the Potomac River.

The announcement “took all of us in the community by surprise,” said Dan Storck, who represents the Mount Vernon district on the Fairfax County Board of Supervisors. “And that should never be the case for an organization that prominent in the community.”


        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

 

Storck supports efforts to rethink the sale of the property and wants AHS to engage with the county and others to examine ways of saving River Farm as a public green space.

So far, the society is keeping quiet through this. Attempts to reach Bob Brackman, interim executive director, and Terry Hayes, chair of the board of directors, were unsuccessful.

It is tempting but perhaps futile to compare the AHS with the granddaddy of them all, Britain’s Royal Horticultural Society. Their respective size is so disparate as to be practically incomparable, but the RHS does at least demonstrate that an invention of the 19th century can still be a potent force for gardening, in

Continue reading

Tricida Announces Twelve Data Presentations on Veverimer and Metabolic Acidosis to be Given at the Virtual American Society of Nephrology Kidney Week 2020

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today that it has authored or sponsored 12 presentations at the upcoming American Society of Nephrology (ASN) Kidney Week 2020 being held virtually October 22-25, 2020. Data to be presented at multiple sessions at the meeting will expand the breadth of information about the implications of metabolic acidosis and CKD. All Tricida presentations will be available on Thursday, October 22, 2020 at 10:00am ET. Session and presentation titles are listed below:

Session Title: CKD Risk Factors: Diet, Environment, Lifestyle

Title:

Relationship Between Metabolic Acidosis and Chronic Kidney Disease Progression is Evident Across United States Racial and Ethnic Groups

Author:

N. Tangri et al.

ePoster #:

PO0468

 

 

Title:

Metabolic Acidosis is Associated with Chronic Kidney Disease Progression: A Longitudinal Analysis of >100,000 United States Community-Based Patients

Author:

V. Mathur et al.

ePoster #:

PO0469

 

 

Title:

Metabolic Acidosis and Progression to Renal Replacement Therapy (Encore Presentation)

Author:

V. Mathur et al.

ePoster #:

PO0467

Session Title: Advances in Geriatric Nephrology

Title:

Effects of Veverimer on Serum Bicarbonate and Physical Function in Elderly Patients with Metabolic Acidosis in Chronic Kidney Disease

Author:

D. Wesson et al.

ePoster #:

PO1685

 

 

Title:

Correlation Between Patient-Reported Physical Limitation and Objective Physical Performance on the Repeated Chair Stand Test Among Patients with Non-Dialysis Dependent Chronic Kidney Disease and Metabolic Acidosis

Author:

V. Mathur et al.

ePoster #:

PO1687

Session Title: CVD, BP, and Kidney Diseases: Exploring the Link

Title:

No Adverse Effects of Veverimer on Volume Status or Blood Pressure in Patients with Chronic Kidney Disease and Metabolic Acidosis

Author:

D. Wesson et al.

ePoster #:

PO2116

Session Title: Women’s Health and Kidney Diseases

Title:

Effects of Veverimer on Serum Bicarbonate and Physical Function in Women with Chronic Kidney Disease: A Subgroup Analysis from a Randomized Controlled Trial

Author:

V. Mathur et al.

Session:

Women’s Health and Kidney Diseases

ePoster #:

PO2612

Session Title: Diabetic Kidney Disease: Clinical – 2

Title:

Effects of Veverimer on Serum Bicarbonate and Physical Function in Patients with Diabetes and Chronic Kidney Disease: Subgroup Analysis from a Randomized Trial (Encore presentation)

Author:

D. Wesson et al.

ePoster #:

PO1033

Session Title: Fluid, Electrolyte, and Acid-Base Disorders: Clinical – 2

Title:

Metabolic Acidosis is a Predictive Factor for All-Cause Mortality in Patients with Chronic Kidney Disease (Encore presentation)

Author:

N. Tangri et al.

ePoster #:

PO1483

Session Title: Pharmacology (PharmacoKinetics, -Dynamics, -Genomics)

Title:

Action of Veverimer on Gastrointestinal Acid Binding is Not Affected by Omeprazole

Author:

D. Parsell et al.

ePoster #:

PO2374

 

 

Title:

Evaluation of Veverimer Drug Interaction Potential (Encore presentation)

Author:

J. Shao et al.

ePoster #:

PO2373

Session Title: Informational Posters

Title:

Understanding the Long-Term Impact of Metabolic Acidosis in Chronic Kidney Disease: Design of the ULTIMA-CKD Patient Registry

Author:

V. Mathur et al.

ePoster #:

INFO16

Continue reading

Dicerna to Present Nedosiran Data at American Society of Nephrology (ASN) Kidney Week 2020

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that clinical data on nedosiran, an investigational candidate for the treatment of primary hyperoxaluria (PH), will be presented during the American Society of Nephrology (ASN) Kidney Week taking place Oct. 22-25, 2020. In addition, a commercial claims analysis of clinical and economic burden associated with PH will also be presented.

The following poster presentations will be available during the “Genetic Diseases of the Kidneys: Non-Cystic – 1” session taking place on Thursday, Oct. 22, 2020 at 10:00 a.m. ET:

  • Title: PHYOX™3: A Long-Term, Open-Label Extension Trial of Nedosiran in Patients With Primary Hyperoxaluria Type 1, 2 or 3
    Poster #: PO1625

About Primary Hyperoxaluria

Primary hyperoxaluria (PH) is a family of ultra-rare, life-threatening genetic disorders that initially manifest with complications in the kidneys. There are three known types of PH (PH1, PH2 and PH3), each resulting from a mutation in one of three different genes. These genetic mutations cause enzyme deficiencies that result in the overproduction of a substrate called oxalate. Abnormal production and accumulation of oxalate leads to recurrent kidney stones, nephrocalcinosis and chronic kidney disease that may progress to end-stage renal disease, requiring intensive dialysis. Compromised renal function eventually results in the accumulation of oxalate in organs ranging from skin, bones, eyes and heart. In the most severe cases, symptoms start in the first year of life. A combined liver-kidney transplantation may be undertaken to resolve PH1 or PH2, but it is an invasive solution with limited availability and high morbidity that requires lifelong immune suppression to prevent organ rejection. There are currently no approved medications for the treatment of PH. Patients are limited to using hyperhydration and medication to attempt to increase solubility of oxalate in urine. Despite these interventions, oxalate may continue to accumulate in the kidneys and other organs, causing damage.

About Nedosiran

Nedosiran is the only RNAi drug candidate in development for primary hyperoxaluria (PH) types 1, 2 and 3 and is Dicerna’s most advanced product candidate utilizing the proprietary GalXC™ RNAi technology platform. Nedosiran is designed to reduce the levels of hepatic lactate dehydrogenase (LDH) enzyme – an enzyme that catalyzes the final step in a common pathway resulting in oxalate overproduction in patients with PH1, PH2 and PH3. Dicerna is evaluating the safety and efficacy of nedosiran in patients with all known forms of PH as part of its PHYOX™ clinical development program.

About Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) is a biopharmaceutical company focused on discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. Using our proprietary RNAi technology platform called GalXC™, Dicerna is committed to developing RNAi-based therapies with the potential to treat both rare and more prevalent diseases. By silencing disease-causing genes, Dicerna’s GalXC platform has the potential to address conditions that are difficult to treat with other modalities.

Continue reading

Chemist elected a 2020 fellow of the American Physical Society

Richard Kaner, who is the Dr. Myung Ki Hong Professor of Materials Innovation, has been elected a 2020 fellow of the American Physical Society, a nonprofit organization that advances the knowledge of physics and represents more than 55,000 members worldwide, including physicists in universities, national laboratories and industry.

The society selected 163 fellows in late September and praised Kaner for “outstanding contributions to the physics, chemistry, and materials science of nanostructured conducting polymers, superhard metals, and new forms of carbon including superconducting fullerides, carbon nanoscrolls, and graphene.” Kaner is a distinguished professor of chemistry and biochemistry, and of materials science and engineering, and a member of the California NanoSystems Institute at UCLA.

Kaner and his research team have designed a series of remarkable devices. One device creates electricity from falling snow. Kaner and UCLA researcher Maher El-Kady, call the device a snow-based triboelectric nanogenerator, or snow TENG, and reported this first-of-its-kind device June, 2019 in the journal Nano Energy. His research team has also produced a separation membrane that separates oil from water and cleans up the debris left by oil fracking. Kaner, El-Kady and colleagues designed a device in 2017 that can use solar energy to inexpensively and efficiently create and store energy, which could be used to power electronic devices, and to create hydrogen fuel for eco-friendly cars. 

Kaner is among the world’s most influential and highly cited scientific researchers. He has also been selected as the recipient of the American Institute of Chemists 2019 Chemical Pioneer Award, which honors chemists and chemical engineers who have made outstanding contributions that advance the science of chemistry or greatly impact the chemical profession.

Source Article

Continue reading

Allergan Aesthetics To Present Data From 4 Abstracts At The 2020 American Society For Dermatologic Surgery Virtual Meeting

IRVINE, Calif., Oct. 9, 2020 /PRNewswire/ — Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced today that it will present 4 abstracts at the annual American Society for Dermatologic Surgery (ASDS) virtual meeting from October 9-11, 2020.

The scheduled times (noted in local Eastern Standard Time) of the presentations, titles and authors are as follows.

Oral presentations include:

  • Patient Satisfaction Following Chin Augmentation With Hyaluronic Acid Fillers: A Pooled Analysis
  • Authors: Joely Kaufman, Patricia Ogilvie, Kenneth Beer, Alexander Rivkin, Sarah Baradaran, Andrew Schumacher
  • Presenter: Joely Kaufman, MD
  • Saturday, October 10th, 11:27 a.m.
  • Treatment of Upper Facial Lines With OnabotulinumtoxinA Results in Long-Lasting Efficacy and Patient Satisfaction
    • Authors: Joel L. Cohen, Koenraad De Boulle, Steven Fagien, Jean Carruthers, Sue Ellen Cox, Patricia Ogilvie, Julie Garcia, Sara Sangha
    • Presenter: Joel L. Cohen, MD
    • Sunday, October 11th, 10:27 a.m.

    The following posters will be on display and available for the entire length of the ASDS Virtual Annual Meeting.

    • Safety, Pharmacodynamic Response, and Treatment Satisfaction With OnabotulinumtoxinA 40 U, 60 U, and 80 U in Subjects With Moderate to Severe Dynamic Glabellar Lines
    • Authors: Sue Ellen Cox, John H. Joseph, Steven Fagien, Dee Anna Glaser, Suzanne Bruce, Edward Lain, Steven Yoelin, Melanie Palm, Corey S. Maas, Xiaofang Lei, John Maltman, Sara Sangha, Mitchell Brin
  • Global Patient Perspectives on Skin Quality in Facial Aesthetics
    • Authors: Noëlle Sherber, Annie Chiu, Arisa Ortiz, Shannon Humphrey, Jeanine Downie, Sabrina Fabi

    Complete abstracts, details on presentation times and changes to presentation dates can be found on the ASDS website. The above listed dates are subject to change. Please check www.asds.net for the latest information.

    IMPORTANT SAFETY INFORMATION & APPROVED USES
    BOTOX® Cosmetic may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of BOTOX® Cosmetic:

    • Problems swallowing, speaking, or breathing, due to weakening of associated muscles, can be severe and result in loss of life. You are at the highest risk if these problems are pre-existing before injection. Swallowing problems may last for several months.
    • Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms including: loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, and trouble swallowing.

    BOTOX® Cosmetic dosing units are not the same as, or comparable to, any other botulinum toxin product.
    There has not been a confirmed serious case of spread of toxin effect when BOTOX® Cosmetic has been used at the recommended dose to treat frown lines, crow’s feet lines, and/or forehead lines.
    BOTOX® Cosmetic may cause loss of strength or general

    Continue reading